PT - JOURNAL ARTICLE AU - E. Jeffries AU - B. Willoughby AU - W. J. Boyko AU - M. T. Schechter AU - B. Wiggs AU - S. Fay AU - M. O'Shaughnessy TI - The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody DP - 1985 Jun 15 TA - Canadian Medical Association Journal PG - 1373--1377 VI - 132 IP - 12 4099 - http://www.cmaj.ca/content/132/12/1373.short 4100 - http://www.cmaj.ca/content/132/12/1373.full SO - CMAJ1985 Jun 15; 132 AB - Testing for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in 448 participants in the Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study. The overall prevalence rate of seropositivity was 34%. Of 130 seronegative subjects followed for an average of 8.5 months, 14 became seropositive; thus, the approximate annual seroconversion rate was 15%. More than 100 male sexual partners in one's lifetime, frequent receptive anal intercourse, fisting, a history of gonorrhea or hepatitis, and frequent sexual contact in clubs were found to be independent risk factors for HTLV-III seropositivity.